ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1821

Demethylated CD4+CD28+KIR+CD11ahi T Cells Are Characterized By a Pro-Inflammatory Transcriptome and Interact with Genetic Risk to Predict Disease Activity in Lupus

Paul Renauer1, Patrick Coit1, Faith Strickland2, Elizabeth Gensterblum1, Mikhail Ognenovski1, Bruce Richardson3 and Amr Sawalha4, 1Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2Rheumatology, University of Michigan, Ann Arbor, MI, 3Rheumatology, University of Michigan and the Ann Arbor VA, Ann Arbor, MI, 4Internal Medicine-Rheumatology, University of Michigan, Ann Arbor, MI

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Genetic Biomarkers, Lupus, T cells and methylation

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  T cell DNA methylation defects play an important role in the pathogenesis of systemic lupus erythematosus. A CD4+CD28+ T cell subset characterized by overexpression of methylation sensitive genes, including CD11a and the KIR gene cluster, has been recently described in autoimmunity. The goal of this study was to characterize this T cell subset in vitro and in patients with SLE.

Methods:  The size of the CD4+CD28+KIR+CD11ahi T cell subset was determined by flow cytometry in 49 female lupus patients of European descent. SLEDAI scores were calculated at the time of blood draw, and all patients were genotyped across 43 confirmed lupus susceptibility loci and a total genetic risk score for lupus was calculated. CD4+CD28+KIR+CD11ahi and CD4+CD28+KIR-CD11alow T cells were isolated from peripheral blood samples of normal healthy individuals after in vitro treatment with 5-azacytidine, and genome-wide DNA methylation and RNA sequencing was performed in both subsets. RNA sequences in the CDR3 region were used to assess the TCR repertoire.

Results:  The CD4+CD28+KIR+CD11ahi T cell subset size correlated with disease activity in lupus patients as measured by SLEDAI score (r=0.36, P= 0.012). Linear regression models suggest that the subset size is a better predictor of disease activity when normalized for total genetic risk in each individual (r=0.42, P=0.003), suggesting that the relationship between KIR+CD11ahi T cell subset size and disease activity in lupus is influenced by genetic risk. Genome-wide DNA methylation analysis identified a total of 31,019 differentially methylated sites in KIR+CD11ahi compared to autologous KIR-CD11alow T cells, with 30,736 methylation sites (99.1%) being hypomethylated. RNA sequencing analysis identified 1,620 overexpressed genes in the KIR+CD11ahi T cell subset, including key pro-inflammatory cytokine genes, adhesion molecules, Fc-gamma receptor genes, Toll-like receptor genes, HLA molecules, and metalloproteinases. Of particular interest, and similar to what is known in lupus T cells, the experimentally derived demethylated KIR+CD11ahi T cell subset demonstrates reduced IL-2 mRNA expression (3.3-fold). Bioinformatics analysis of 718 genes that are hypomethylated and overexpressed in KIR+CD11ahi T cells revealed significant enrichment in pro-inflammatory gene ontologies, pathways, and gene meta-groups. Analysis of the TCR repertoire suggests that the KIR+CD11ahi T cell subset is polyclonal, but with less diverse clonality compared to autologous KIR-CD11alow T cells (mean number of TCR clones 673±72 versus 837±39; P= 0.001).

Conclusion:  CD4+CD28+KIR+CD11ahi T cells are polyclonal and demethylated, and characterized by a pro-inflammatory transcriptional profile. These cells are expanded in lupus patients, and interact with total genetic risk to predict and possibly contribute to disease activity.


Disclosure: P. Renauer, None; P. Coit, None; F. Strickland, None; E. Gensterblum, None; M. Ognenovski, None; B. Richardson, None; A. Sawalha, None.

To cite this abstract in AMA style:

Renauer P, Coit P, Strickland F, Gensterblum E, Ognenovski M, Richardson B, Sawalha A. Demethylated CD4+CD28+KIR+CD11ahi T Cells Are Characterized By a Pro-Inflammatory Transcriptome and Interact with Genetic Risk to Predict Disease Activity in Lupus [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/demethylated-cd4cd28kircd11ahi-t-cells-are-characterized-by-a-pro-inflammatory-transcriptome-and-interact-with-genetic-risk-to-predict-disease-activity-in-lupus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/demethylated-cd4cd28kircd11ahi-t-cells-are-characterized-by-a-pro-inflammatory-transcriptome-and-interact-with-genetic-risk-to-predict-disease-activity-in-lupus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology